Activation of AMP-activated Protein Kinase by Temozolomide Contributes to Apoptosis in Glioblastoma Cells via p53 Activation and mTORC1 Inhibition

Methylating drugs such as temozolomide (TMZ) are widely used in the treatment of brain tumors including malignant glioblastoma. The mechanism of TMZ-induced glioblastoma cell death and apoptosis, however, is not fully understood. Here, we tested the potential involvement of AMP-activated protein kinase (AMPK) in this process. We found that methylating agents TMZ and N-methyl-N’-nitro-N-nitrosoguanidine induce AMPK activation in primary cultured human glioblastoma and glioblastoma cell lines. TMZ-induced O6-methylguanine production is involved in AMPK activation. O6-benzylguanine, an O6-methylguanine-DNA methyltransferase inhibitor, enhances TMZ-induced O6-methylguanine production, leading to enhanced reactive oxygen species production, which serves as an upstream signal for AMPK activation. Activation of AMPK is involved in TMZ-induced glioblastoma cell death and apoptosis. AMPK inhibitor (Compound C) or AMPKα siRNA knockdown inhibits TMZ-induced glioblastoma cell death and apoptosis, whereas AMPK activator 5-aminimidazole-4-carboxamide-1-β-D-ribofuranoside enhances it. In further studies, we found that activation of AMPK is involved in TMZ-induced p53 activation and subsequent p21, Noxa, and Bax up-regulation. Activation of AMPK by TMZ also inhibits mTOR complex 1 (mTORC1) signaling and promotes anti-apoptosis protein Bcl-2 down-regulation, which together mediate TMZ-induced pro-cell apoptosis effects. Our study suggests that activation of AMPK by TMZ contributes to glioblastoma cell apoptosis, probably by promoting p53 activation and inhibiting mTORC1 signaling.

Astrocytic tumors are the most common primary brain tumors. Of the astrocytic tumors, malignant glioblastoma is the most malignant form and has the worst prognosis. Complete surgical resection of glioblastoma is difficult, and the tumor generally recurs within a year after radiation and chemotherapy regardless of the initial response to these treatment modalities (1). Of the chemotherapeutic agents used to treat glioblastoma, alkylating agents including O6-methylating agent temozolomide (TMZ) are the most widely used.

Despite the use of O6-methylating agents (TMZ for example) in glioblastoma therapy, the median survival times of patients suffering from the most severe form glioblastoma are still remarkably low (12–14 months). There is an urgent need for improving glioblastoma therapy. One goal that needs to be reached in achieving this would be to improve our knowledge of the mechanism of alkylating agent-induced death in glioblastoma cells (2). Here, we focus on AMPK, a recently discovered kinase that is involved in anti-tumor growth/survival effects (3–9).

AMP-activated protein kinase (AMPK) is a metabolic-sensing protein kinase, which plays an essential role as an energy-sensor mainly in ATP-deprived conditions (10). In the activated states, AMPK down-regulates several anabolic enzymes and thus shuts down the ATP-consuming metabolic pathways. Interestingly, several recent reports have observed the strong pro-apoptotic potential of AMPK in activated conditions such as AMPK activator 5-aminimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR)-treated cells or constitutively active AMPK mutant (3, 5–9, 11). For example, activation of AMPK by AICAR inhibits the growth of EGFR receptor vIII-expressing glioblastomas (5). Interestingly, certain chemotherapy drugs can also activate AMPK, mediating pro-cell death and apoptosis effects (12). For example, a recent paper suggests that AMPK activation is a key player for doxorubicin-induced cancer cell apoptosis (12). However, the potential effects of AMPK activation on TMZ-induced glioblastoma cell death and apoptosis have not been studied.

Here, we found for the first time that methylating agents TMZ and N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) induce AMPK activation in both primary cultured human glioblastoma cells and glioblastoma cell lines, which mediates cell death and apoptosis. We found that activation of AMPK is

---

Wen-bin Zhang‡§1, Zhuo Wang‡1, Fei Shu†, Yong-hua Jin†, Hong-yi Liu†, Qiu-juan Wang†, and Yong Yang‡2

From the ‡Department of Physiology, China Pharmaceutical University, Nanjing 210009 and the Departments of §Neurosurgery and †Psychiatry, Brain Hospital Affiliated with Nanjing Medical University, Nanjing 210029, China

---

*This work was supported by National Natural Science Foundation of China Grants 30701032 and 81072661, the New Century Excellent Talents Program supported by Ministry of Education of China (2009) (Y. Y.), Fundamental Research Funds for the Central Universities Grant JZK2009006, Natural Science Foundation of Jiangsu Province Grant BK2009298, and "Major Drug Discovery" science and technology major projects of China Grant 2009ZX09303-001.

† The on-line version of this article (available at http://www.jbc.org) contains supplemental Fig. S1.

§ These authors contributed equally to this paper.

1 To whom correspondence may be sent: 24 Tongjiachang, Nanjing 210009, China. Tel.: 86-025-83271132; Fax: 86-025-83271132; E-mail: valianty@hotmail.com.
Temozolomide Activates AMPK in Glioblastoma Cells

involved in TMZ-induced p53 activation and mTORC1 inhibition.

**EXPERIMENTAL PROCEDURES**

**Chemicals and Reagents**—AKT1, T-S6K, AMPKα1, AMPKα2, TSC1 (Hamartin), TSC2 (Tuberin), Bcl-2, Bcl-XL, p21, p53, AKT, ERK1/2, LKB1, goat anti-rabbit IgG-HRP, and goat anti-mouse IgG-HRP antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Compound C, rapamycin, and AICAR were purchased from Calbiochem (San Diego, CA). Oβ-benzylguanine (Oβ-BG), TMZ, MNNG, monoclonal mouse anti-β-actin, H2O2, and N-acetylcysteine (NAC) were obtained from Sigma (St. Louis, MO). T-AMPKα and all phosphorylation antibodies were purchased from Cell Signaling Technology (Beverly, MA).

**Primary Human Glioblastoma Cell Cultures**—Following informed consent, tumor samples classified as glioblastoma based on World Health Organization (WHO) criteria were obtained from patients undergoing surgical treatment at Brain Hospital affiliated with Nanjing Medical University. Within 1–3 h after surgical removal, tumors were washed and enzymatically dissociated into single cells. Red blood cells were removed by differential centrifugation. Tumor cells were then cultured serum medium consisting of DMEM (Invitrogen) with 10% FBS (Sigma), penicillin/streptomycin (1:100; Sigma) and 4 mM L-glutamine (Sigma), in a CO2 incubator at 37 °C.

**Cell Culture**—Glioblastoma U87MG and U373MG cells were maintained in DMEM (Sigma), supplemented with a 10% FBS (Sigma), penicillin/streptomycin (1:100; Sigma) and 4 mM L-glutamine (Sigma), in a CO2 incubator at 37 °C.

**Cell Viability Assay (MTT Dye Assay)**—Cell viability was measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. Briefly, cells were collected and seeded in 96-well plates at a density of 5 × 104 cells/cm2. Different seeding densities were optimized at the beginning of the experiments. 20 μl of MTT tetrazolium salt (Sigma) dissolved in Hanks’ balanced solution at a concentration of 5 mg/ml was added to each well with the indicated treatment and incubated in CO2 incubator for 4 h. Finally, the medium was aspirated from each well, and 150 μl of dimethyl sulfoxide (Sigma) was added to dissolve formazan crystals, and the absorbance of each well was obtained using a Dynatech MR5000 plate reader at a test wavelength of 490 nm with a reference wavelength of 630 nm.

**Western Blotting**—Aliquots of 40 μg of protein from each sample were separated by 10–12% SDS-PAGE and transferred onto a PVDF membrane (Millipore, Bedford, MA). After blocking with 10% instant nonfat dry milk for 1 h, membranes were incubated with specific antibodies overnight at 4 °C followed by incubation with secondary antibodies for 1 h. Antibody binding was detected with the enhanced chemiluminescence (ECL) detection system (Amersham Biosciences).

**Immunoprecipitation**—U87MG cells treated with the appropriate stimuli were treated with lysis buffer, 200 mM NaCl (pH 7.4), 1% Triton X-100, 10% glycerol, 0.3 mM EDTA, 0.2 mM Na3VO4, and protease inhibitor mixtures (Roche Applied Sciences). Aliquots of 800 μg of proteins from each sample were precleared by incubation with 20 μl of protein A/G-Sepharose (beads) (Amersham Biosciences) for 1 h at 4 °C. Precleared samples were incubated with primary antibodies in lysis buffer overnight at 4 °C. To this was added 35 μl of protein A/G beads, and the samples were incubated for 2 h at 4 °C. The beads were washed five times with phosphate-buffered saline (PBS) and once with lysis buffer, boiled, separated by 10% SDS-PAGE, and transferred onto a PVDF membrane followed by Western blotting analysis.

**Quantification of Apoptotic Cells**—To detect apoptotic cells, cells were stained with DNA dye Hoechst 33342 (Sigma). Cells with the indicated treatment were fixed with 4% formaldehyde in PBS for 10 min at 4 °C. Cells were then incubated with 5 μg/ml Hoechst 33342 to stain the nuclei for 5 min. After washing with PBS, the apoptotic cells were observed under a confocal fluorescence microscope (Leica TCS SMD FCS, Leica, Germany). Cells exhibiting condensed chromatin nuclei (Hoechst 33342 stain, Blue) were scored as apoptotic cells. For each Hoechst experiment, at least 100 cells in five random scope fields were counted for apoptotic rate.

**The Cell Apoptosis ELISA Detection Kit** (Roche Applied Science) was used to detect apoptosis in glioblastoma cell lines with different treatments according to the manufacturer’s protocol. Briefly, after the indicated treatments, the cytoplasmic histone/DNA fragments from cells were extracted and bound to immobilized anti-histone antibody. Subsequently, the peroxidase-conjugated anti-DNA antibody was used for the detection of immobilized histone/DNA fragments. After the addition of substrate for peroxidase, the spectrophotometric absorbance of the samples was determined by using Dynatech MR5000 plate reader at 405 nM.

**RNA Interference (RNAi)**—siRNA for AMPKα1/α2 (sc-45312), LKB1 (sc-35816), ATM (sc-29761), and Bcl-2 (sc-29214) were purchased from Santa Cruz Biotechnology. SignalSilence® mTOR siRNA was purchased from Cell Signaling Technology. U87MG or primary cultured glioblastoma cells were cultured and seeded in a 6-well plate 1 day prior to transfection and cultured to 70% confluence the following day. For RNAi experiments, 3.2 μl of PLUS™ Reagent (Invitrogen) was diluted in 90 μl of RNA dilution water (Invitrogen) for 5 min in room temperature. Then, 10 μl of siRNA (10 μM) or control (scramble) siRNA (10 μM) was added to the PLUS™ Reagent and incubated for 5 min at room temperature. 3.6 μl of Lipofectamine (Invitrogen) was then added to the complex. After a 30-min incubation, the transfection complex was formed. Finally, the complex was added to the wells containing 1 ml of medium with the final siRNA concentration of 100 nM. Target protein expression was determined by Western blotting 48 h after transfection, successfully knocked down cells were used for further experiments.

**p53 and TSC1/2 shRNA**—Human TSC1 (sc-37437-SH)/TSC2 (sc-37437-SH) and p53 shRNA (sc-29435-sh) plasmids were purchased from Santa Cruz Biotechnology. U87MG cells were cultured and seeded in a 6-well plate 1 day prior to transfection and cultured to 70% confluence the following day. For shRNA experiments, 3.2 μl of PLUS™ Reagent was diluted in 90 μl of RNA dilution water for 5 min in room temperature. Then, 2 μg of plasmid or 2 μg of control plasmid was added to the
FIGURE 1. TMZ induces AMPK activation in glioblastoma cells. Glioblastoma cell line U87MG (A and B) or U373MG (C and D) was treated with TMZ (250 μM) and cultured for different time points (0, 2, 4, 8, and 12 h) or treated with different doses of TMZ (0, 50, 250, and 500 μM) and cultured for 8 h. p-AMPK (Thr-172), T-AMPK, p-ACC (Ser-79), p-LKB1 (Ser-428), and β-actin were detected by Western blotting. AMPK phosphorylation was quantified. U87MG cells were treated with different doses of TMZ (0, 50, 250, and 500 μM), and cell apoptosis was detected by Hoechst 33342 assay (E and quantified in F) and histone/DNA ELISA (G) 36 h later. Cell viability was detected by MTT assay (H) 48 h after TMZ treatment. Primary cultured human glioblastoma cells (I and J) were treated with TMZ (250 μM) and cultured for different time points (0, 2, 4, 8, and 12 h) or treated with different doses of TMZ (0, 50, 150, 250, and 500 μM) and cultured for 8 h. p-AMPK (Thr-172), T-AMPK, p-ACC (Ser-79), and p-LKB1 (Ser-428) were detected by Western blotting. Experiments in this figure were repeated at least three times, and similar results were obtained. *, p < 0.05 versus untreated group (Ctrl lane) (ANOVA). Scale bar, 25 μm.
Temozolomide Activates AMPK in Glioblastoma Cells

A

B

C

D

E

F

G

H

I

J

K

L

M

Temozolomide Activates AMPK in Glioblastoma Cells

A

B

C

D

E

F

G

H

I

J

K

L

M

Temozolomide Activates AMPK in Glioblastoma Cells

A

B

C

D

E

F

G

H

I

J

K

L

M
PLU$^{\text{+}}$ Reagent and incubated for 5 min at room temperature. 3.6 μl of Lipofectamine was then added to the complex. After a 30-min incubation, the transfection complex was formed and added to U87MG cells. Cells were then cultured for additional 48 h, followed by puromycin (0.5 μM) selection. TSC2/TSC1 or p53 expression was detected by Western blotting 48 h later. Successfully transfected stable cells were cultured and stored for further experiments.

Reactive Oxygen Species (ROS) Production Detection—Cultured U87MG cells were loaded with 1 μM fluorescent dye dihydrodorhamidine 2 h before treatment, which reacts with ROS in cells and results in a change of fluorescence. After the indicated treatments, U87MG cells were trypsinized, suspended in ice-cold PBS, and fixed in 70% ethyl alcohol at −20 °C. The changes in fluorescence in drug-treated cells were quantified by fluorescence-activated cell sorter analysis. Induction of ROS generation was expressed in arbitrary units (versus control).

Statistical Analysis—The values in the figures are expressed as the means ± S.D. The figures in this study are representative of at least three independent experiments. Values of p < 0.05 were considered as statistically significant (ANOVA) with a Newman-Keuls post test.

RESULTS

TMZ Induces AMPK Activation in Glioblastoma Cells—First, we tested the possible effect of TMZ on AMPK activation in cultured glioblastoma cells. Essential to activation of AMPK is its phosphorylation at Thr-172 by an upstream kinase LKB1 (13). LKB1 is activated allosterically by binding to the pseudokinase STRAD and the adaptor protein MO25. The LKB1-STRAD-MO25 heterotrimeric complex represents the biologically active unit that is capable of phosphorylating and activates AMPK. Phosphorylation of LKB at Ser-428 influences the ability of LKB1 to bind and phosphorylate AMPK at Thr-172 (14). After AMPK activation, AMPK phosphorylates and inactivates acetyl-CoA carboxylase (ACC) (Ser-79) (15), which is well established as a key indicator for AMPK activity. As shown in Fig. 1, A–D, in two different glioblastoma cell lines (U87MG and U373MG), TMZ clearly induced AMPK and its upstream molecular LKB1 and downstream molecular ACC phosphorylation in a both time- and dose-dependent manner. As expected, TMZ induced U87MG cell death (Fig. 1, H, reduced cell viability, MTT assay) and cell apoptosis (Fig. 1, E–G) in a dose-dependent manner, the cell apoptosis was confirmed by two different methods including Hoechst 33342 assay (Fig. 1, E and F) and histone/DNA ELISA (Fig. 1G). Importantly, TMZ also induced strong AMPK activation in primary cultured human glioblastoma cells in a both dose- and time-dependent manner (Fig. 1, I and J).

O6-MeG, ROS, and LKB1 Are Involved in TMZ-induced AMPK Activation—As shown in Fig. 1, TMZ induced strong AMPK activation in cultured glioblastoma cells. Further, MNNG, another DNA-methylating agent, was also able to induce AMPK activation (Fig. 2A). We then tested the possible upstream signals for AMPK activation by TMZ. Previous studies have identified ROS as strong AMPK activators (16–18), so we next tested the possible involvement of ROS production in TMZ-induced AMPK activation. As shown in Fig. 2C, TMZ induced ROS production in U87MG cells, NAc, an antioxidant, largely inhibited TMZ-induced ROS production and AMPK activation (Fig. 2, C and F). As expected, direct H2O2 treatment induced strong AMPK activation; so did the AMPK activator AICAR (Fig. 2D). Here, we suggest that ROS production that leads to AMPK activation by TMZ is associated with induction of DNA damage. To support this, we found that O6-BG, an O6-methylguanine-DNA methyltransferase (MGMT) inhibitor, which is reportedly to enhance TMZ-induced O6-MeG production (the lethal DNA damage by TMZ) (2, 19, 20), caused enhanced ROS generation and downstream AMPK activation (Fig. 2, B and C). Further, the other DNA-methylating agent MNNG was also able to induce ROS production and AMPK activation, which was also enhanced by O6-BG (Fig. 2, A–C). So, we indicate that TMZ causes DNA damage which leads to ROS production, the latter serving as an upstream signal for AMPK activation. Knockdown of LKB1 by specific siRNA reduced TMZ-induced AMPK activation, indicating that LKB1 might be the upstream signal for AMPK activation in response to TMZ (Fig. 2E). Importantly, NAc and Compound C, which inhibited TMZ-induced AMPK activation (Fig. 2F), also inhibited TMZ-induced cell death (reduced cell viability) and apoptosis (detected by Hoechst staining and histone/DNA ELISA) (Fig. 2, G–I). Further, knockdown of the upstream signal LKB1 also diminished TMZ-induced cell death and apoptosis (Fig. 2, K–M). These results indicated that AMPK activation might be involved in TMZ-induced cell death/apoptosis in cultured glioblastoma cells.

AMPK Activation Is Involved in TMZ-induced Cell Death/Apoptosis in Vitro—To confirm further that AMPK activation is involved in TMZ-induced glioblastoma cell death/apoptosis, AMPKα siRNA was used. As shown in Fig. 3A, AMPKα1/2 siRNAs efficiently knocked down both AMPKα1 and AMPKα2 in cultured U87MG cells, whereas control (scramble) siRNA had almost no effect on AMPKα1/2 expression. TMZ-induced cell death and apoptosis were largely inhibited in AMPKα1/2

---

**FIGURE 2.** O6-MeG, ROS, and LKB1 are involved in TMZ-induced AMPK activation. A, glioblastoma U87MG cells were treated with 10 μM MNNG and cultured for 4, 8, and 12 h. p-AMPKα (Thr-172), p-ACC (Ser-79), p-LKB1 (Ser-428), T-AMPKα, and ERK1/2 were detected by Western blotting. B, U87MG cells were either left untreated or pretreated with O6-BG (10 μM) for 2 h, followed by TMZ (250 μM) or MNNG (10 μM) treatment for 8 h. AMPK activation was detected by Western blotting using the antibodies mentioned above. C, U87MG cells were pretreated with anti-oxidant NAc (400 μM) or O6-BG (10 μM) for the indicated time periods, followed by TMZ (250 μM) or MNNG (10 μM) treatment and cultured for the indicated times. ROS production was detected. D, U87MG cells were treated with 500 μM H2O2 or 1 μM AICAR and cultured for 2 and 4 h. p-AMPKα, p-ACC, and β-actin were detected by Western blotting. E, U87MG cells transfected with scramble (control) or LKB1 siRNAs were treated with 250 μM TMZ. LKB1/AMPK activation was detected by Western blotting. U87MG cells were pretreated with 10 μM Compound C (CC) or NAc (400 μM) for 2 h, followed by TMZ (250 μM) treatment. AMPK activation was detected by Western blotting 4 and 8 h later (F). cell viability was detected by MTT assay after 48 h (G), cell apoptosis was detected by histone/DNA ELISA (H), and Hoechst staining (I) and quantified in J after 36 h. U87MG cells transfected with scramble (Ctrl) or LKB1 siRNA were treated with 250 μM TMZ, and cell death and apoptosis were detected using the same methods described above (K–M). Experiments in this figure were repeated at least three times, and similar results were obtained. *p < 0.05 versus TMZ-treated group in Ctrl cells (ANOVA). Scale bar, 25 μM.
knockdown cells (Fig. 3, B–E). However, enforced AMPK activation by AICAR enhanced TMZ-induced cell death and apoptosis in cultured U87MG cells (Fig. 3, F and G). Importantly, knockdown of AMPKα1/2 by specific siRNAs in primary cultured glioblastoma cells (Fig. 3H) also inhibited TMZ-induced cell death and apoptosis (Fig. 3, I and J). Taking these results into account, we suggest that AMPK activation is involved in TMZ-induced cell apoptosis in cultured glioblastoma cells.

**AMPK Activation Is Involved in TMZ-induced p53 Activation in Vitro**—Because we have showed that TMZ induces AMPK activation, which contributes to glioblastoma cell death and apoptosis (Figs. 1–3), we next tried to identity the downstream targets of AMPK activation. We first focused on p53 because p53 is a key mediator for TMZ-induced glioblastoma cell death (2, 21–25), and previous studies have shown that AMPK phosphorylates and activates p53 directly, leading to apoptotic cell death (6, 7). As shown in Fig. 4A, TMZ-induced p53 phosphorylation (at serine 15) and up-regulation/stabilization in U87MG cells. p21 and pro-apoptotic proteins Noxa and Bax were also induced after TMZ treatment (Fig. 4, A). To confirm further the requirement of p53 to TMZ-induced glioblastoma cell apoptosis, we generated a p53 knockdown stable U87MG cell by introducing a p53 shRNA plasmid to wild-type U87MG cells through the methods mentioned above (Fig. 4B). TMZ-induced cell death and apoptosis were largely inhibited in the shRNA-transfected low p53 expression stable U87MG cells (Fig. 4, K and L), again supporting that requirement of p53 for TMZ-induced cell apoptosis. Further, p53 knockdown by shRNA largely inhibited TMZ-induced p21 and Noxa/Bax expression, suggesting that p21/Noxa/Bax was induced in a p53-dependent manner after TMZ treatment (Fig. 4B). To confirm further the requirement of p53 to TMZ-induced glioblastoma cell apoptosis, we generated a p53 knockdown stable U87MG cell by introducing a p53 shRNA plasmid to wild-type U87MG cells through the methods mentioned above (Fig. 4B). TMZ-induced cell death and apoptosis were largely inhibited in the shRNA-transfected low p53 expression stable U87MG cells (Fig. 4, K and L), again supporting that requirement of p53 for TMZ-induced cell apoptosis. Further, p53 knockdown by shRNA largely inhibited TMZ-induced p53 activation (phosphorylation at Ser-15 and accumulation) as well as downstream p21/Noxa/Bax induction (Fig. 4, C and D), indicating that activation of AMPK is involved in TMZ-induced p53 activation. We then tested whether there was a direct link between AMPK and p53 in TMZ-treated glioblastoma cells by using a co-immunopre-
FIGURE 4. AMPK activation is involved in TMZ-induced p53 activation. A, glioblastoma U87MG cells were treated with 250 μM TMZ and cultured for the indicated times (0, 4, 8, 16, 24, and 48 h). AMPKa1, AMPKa2, ERK1/2, p-AMPKa (Thr-172), p-ACC (Ser-79), phosphorylation (Ser-15) and expression of p53 as well as p21, Noxa, and Bax were detected. B, p53 successfully knocked down U87MG cells (by tranfecting cell with a p53 shRNA plasmid and puromycin selection as described under “Experimental Procedures”) were treated with TMZ (250 μM) and cultured for 24 and 48 h. Phosphorylation (Ser-15) and expression of p53, p21, Noxa, Bax, p-AMPKa (Thr-172) and T-AMPK were detected. C, U87MG cells were pretreated with the AMPK inhibitor Compound C (CC, 10 μM) for 2 h, followed by 250 μM TMZ treatment for 24 h and 48 h. p-AMPKa (Thr-172), p-ACC (Ser-79), T-AMPK, p-p53 (Ser-15), p21, and Bax were detected. D, U87MG cells transfected with control or AMPKa1/2 siRNA were treated with TMZ (250 μM) for 24 and 48 h. p-AMPKa (Thr-172), p-ACC (Ser-79), p-p53 (Ser-15), T-p53, p21, Noxa, Bax, p-AMPKa (Thr-172) and T-AMPK were detected. E, U87MG cells transfected with control or AMPKa1/2 siRNA were treated with TMZ (250 μM) for 24 and 48 h. Phosphorylation (Ser-15) and expression level of p53, p21, Noxa, Bax, and p-ATM (Ser 1981) were detected. I–L, p53 shRNA-transfected stable U87MG cells were treated with TMZ (250 μM). Cell viability was detected by MTT assay after 48 h (K). Cell apoptosis was detected by histone/DNA ELISA (L) after 36 h. Experiments in this figure were repeated at least three times and similar results were obtained. *, p < 0.05 versus same treatment in scramble siRNA-transfected group (ANOVA).
Temozolomide Activates AMPK in Glioblastoma Cells

We performed precipitation assay, and we found that AMPKα formed a complex with p53, where AMPK directly phosphorylates p53 (Ser-15) after TMZ or AICAR treatment (Fig. 4, E–I). Notably, AICAR and H₂O₂, two other AMPK activation agents, were also able to induce p53 activation, which was also inhibited by AMPK siRNA (Fig. 4J). Importantly, the induction of p53/p21 by TMZ was also inhibited by AMPKα1/2 siRNA knockdown in primary cultured human glioblastoma cells (Fig. 5J). Taking all of these results into account, we suggest that TMZ induces AMPK activation, activated AMPK directly binds to and phosphorylates p53, and activated p53 then mediates glioma cell apoptosis, probably by regulation the expression of its downstream target proteins including p21, Noxa, and Bax.

**AMPK Activation Mediates TMZ-induced mTORC1 (mTOR Complex 1) Inhibition in Vitro**—One of the most studied downstream targets of AMPK activation is mTORC1 inhibition. AMPK activation has been postulated to mediate its pro-death/anti-growth effects primarily through mTORC1 inhibition (11, 26, 27). We next tested the effects of TMZ on mTORC1 inhibition. As shown in Fig. 5A, TMZ inhibited the phosphor-
AMPK activation mediates TMZ-induced mTORC1 inhibition in vitro. A, glioblastoma U87MG cells were treated with TMZ (250 μM) for the indicated times. p-56K (Thr-172), p-4E-BP1 (Ser-65), p-S6 (Ser-235/236), T-AIMPKα, and AKT1 were detected. B, U87MG cells transfected with scramble (Ctrl) or AMPKα1/2 siRNA were treated with TMZ (250 μM) for 24h, p-4E-BP1 (Ser-65), p-S6 (Ser-235/236), and relative loading controls were detected. C, U87MG cells were pretreated with Compound C (CC) (10 μM) for 2 h followed by 250 μM TMZ treatment for 24 h. p-56K (Thr-172), AKT1, and T-AIMPKα were detected. D, U87MG cells were transfected with TSC2/TSC1 shRNA for 48 h. Successfully transfected cells were selected by puromycin. After selection, cells were treated with TMZ (250 μM) for 24 h, p-4E-BP1 (Ser-65), p-S6 (Ser-235/236), TSC1, TSC2, and AKT1 were detected. E, glioblastoma U87MG cells were treated with TMZ (250 μM) for the indicated times. Bcl-2 expression was detected by Western blotting. F, U87MG cells were treated with rapamycin (100 nM) for 12 h, mTOR, p-mTOR (Ser-2448), p-56K (Thr-172), p-AKT (Ser-473), p-4E-BP1 (Ser-65), and p-S6 (Ser-235/236) were detected. G, U87MG cells were transfected with scramble (Ctrl) or mTOR siRNA for 48 h. mTOR, p-mTOR (Ser-2448), p-56K (Thr-172), p-AKT (Ser-473), AKT1, and Bcl-2 were detected. H, U87MG cells were transfected with control (scramble) or AMPKα1/2 siRNA were treated with TMZ (250 μM) for 48h. The expression levels of AMPKα1/2, Bcl-2, and β-actin were detected. I, U87MG cells were pretreated with Compound C (CC) (10 μM) for 2 h, followed by 250 μM TMZ treatment for 48 h. Bcl-2 and β-actin were detected. The effects of AICAR (1 mM) and H2O2 (250 μM, 24 h) on Bcl-2 expression were also detected. J, primary cultured human glioblastoma cells transfected with control (scramble) or AMPKα1/2 siRNA were treated with TMZ (250 μM) for 48 h. The expression levels of AMPKα1/2, Bcl-2, p53, p21, Bcl-2, and β-actin were detected. K and L, U87MG cells were pretreated with rapamycin (100 nM) for 2 h, followed by 250 μM TMZ treatment. Cell viability (48 h later) was detected by MTT assay. Cell apoptosis (36 h later) was detected by histone/DNA ELISA. M, U87MG cells were transfected with scramble (Ctrl), mTOR, or Bcl-2 siRNA for 48 h followed by TMZ (250 μM) treatment for another 48 h. Cell viability was detected by MTT assay. N, proposed signal pathway involved in this study is shown. TMZ induces AMPK activation in glioblastoma cells. DNA damage caused by TMZ plays an important role in ROS production and following LKB1/AMPK activation. Activation of AMPK contributes TMZ-induced glioblastoma cell apoptosis, probably by regulating p53 (positively) and mTORC1 (negatively) pathways as well as altering the expression of apoptosis-associated proteins, including p21, Bax, Noxa, and Bcl-2. In addition to AMPK, ATM and possible other DNA repair proteins may also be involved in p53 activation by TMZ. Experiments in this figure were repeated at least three times, and similar results were obtained. *, p < 0.05 versus the TMZ-treated group (ANOVA).
TMZ-induced p53 activation (phosphorylation at Ser-15/up-regulation) and p21 up-regulation (Fig. 4), which is consistent with previous studies. For example, activation of AMPK by AICAR suppresses the growth of hepatoma HepG2 cells and induces expression of wild-type p53 and, secondarily, p21 (35). It also enhances the phosphorylation of Ser-15 in the transactivation domain of p53, which activates p53 and induces apoptosis (6, 7, 36). Intriguingly, this site (Ser-15) is phosphorylated by purified AMPK in vitro (6, 7). In addition, ectopic expression of wild-type AMPK kinase LKB1 inhibits the growth and increases the concentration of p21 in LKB1-deficient A549 lung adenocarcinoma cells (8, 37). By using an immunoprecipitation assay, here we demonstrated that AMPK binds to and phosphorylates p53 (Ser-15) directly in response to TMZ treatment (Fig. 4) and then activates p53 and could be the key mechanism mediates glioblastoma cell death/apoptosis in vitro. Because activation of p53 is so important in regulating the TMZ cytotoxic effect, it is not surprising to see that kinases other than AMPK are also able to regulate p53 phosphorylation (Ser-15) after TMZ treatment. It is noted that knockdown of ATM by siRNA also reduced p53 phosphorylation and accumulation (see supplemental Fig. S1). At this point, we do not know whether there is a direct link between AMPK activation and ATM, and we suggest that AMPK is among several kinases that regulate p53 activation in response to TMZ.

Besides positively regulating p53, AMPK activation might also induce tumor cell death or inhibit tumor cell growth by several other mechanisms, of which, the most studied is by activating TSC2, which then inhibits mTORC1 signaling and protein synthesis (38, 39). The regulation of TSC2 and mTOR by AMPK has special implications because the PI3K-Akt signaling pathway is constitutively active in many cancers, including glioblastomas, most notably those that have either inactivating mutations of the PTEN gene (e.g. gliomas, melanoma, advanced prostate cancer, and endometrial carcinomas) (40) or overexpression of an activated member of the epidermal growth factor (EGF) receptor family (e.g. Her2/NEW in breast cancer) (9, 41).

One important consequence of the constitutive activation of AKT is phosphorylation of TSC2 at a site different from that phosphorylated by AMPK. This leads to inhibition of TSC2, activation of mTORC1 signaling, and an increase in protein synthesis, which have been involved in tumor growth and survival. Here, we show that activation of AMPK inhibits mTORC1 activation after TMZ treatment in glioblastoma cell line (both cell lines and primary culture) in vitro (Fig. 5). Knockdown TSC2 or AMPK reverses the inhibitory effects of TMZ on mTORC1 activation in glioblastoma cell (Fig. 5). Based on these findings, we suggest that activation of AMPK by TMZ inhibits the activation of mTORC1 in a TSC2-dependent manner; inhibition of mTORC1 facilitates TMZ-induced glioblastoma cell death/apoptosis probably by down-regulating pro-apoptosis protein Bcl-2 (Fig. 5).

In summary, here we found for the first time that TMZ induces AMPK activation in cultured glioblastoma cells. ROS production, as a result of DNA damage after TMZ treatment, serves as an upstream signal for LKB1/AMPK activation. Activation of AMPK contributes to TMZ-induced glioblastoma cell apoptosis, probably by promoting p53 activation and inhibiting mTORC1 signaling as well as altering the expression level of apoptosis-related proteins, including p21, Noxa, Bax, and Bcl-2.

REFERENCES
1. Conrad, C. A., Milosavljevic, V. P., and Yung, W. K. (1995) *Neurology* 43, 795–812
2. Roos, W. P., Batista, L. F., Naumann, S. C., Wick, W., Weller, M., Menck, C. F., and Kaina, B. (2007) Oncogene 26, 186–197
3. Garcia-Gil, M., Pesi, R., Perna, S., Allegrini, S., Giannecchini, M., Camici, M., and Tozzi, M. G. (2003) *Neuroscience* 117, 811–820
4. Pan, W., Yang, H., Cao, C., Song, X., Wallin, B., Kivlin, R., Lu, S., Hu, G. D., Wu, W., and Yan, Y. (2008) *Oncol. Rep.* 20, 1553–1559
5. Guo, D., Hildebrandt, J. J., Prins, R. M., Soto, H., Mazzotta, M. M., Dang, J., Czernin, J., Shyy, J. Y., Watson, A. D., Phelps, M., Radu, C. G., Cloughesy, T. F., and Mischel, P. S. (2009) *Proc. Natl. Acad. Sci. U.S.A.* 106, 12992–12997
6. Jones, R. G., Plas, D. R., Kubek, S., Buzza, M., Mu, J., Xu, Y., Birnbaum, M. J., and Thompson, C. B. (2005) *Mol. Cell* 18, 283–293
7. Okoshi, R., Ozaki, T., Yamamoto, H., Ando, K., Koida, N., Ono, S., Koda, T., Kamijo, T., Nakagawara, A., and Kizaki, H. (2008) *J. Biol. Chem.* 283, 3979–3987
8. Xiang, X., Saha, A. K., Wang, L., Ruderman, N. B., and Luo, Z. (2004) *Biochem. Biophys. Res. Commun.* 321, 161–167
9. Luo, Z., Saha, A. K., Xiang, X., and Ruderman, N. B. (2005) *Trends Pharmacol. Sci.* 26, 69–76
10. Hardie, D. G., Carling, D., and Carlson, M. (1998) *Annu. Rev. Biochem.* 67, 821–855
11. Cao, C., Lu, S., Kivlin, R., Wallin, B., Card, E., Bagdasarian, A., Tamakloe, T., Chu, W. M., Guan, K. L., and Wan, Y. (2008) *J. Biol. Chem.* 283, 28897–28908
12. Ji, C., Yang, B., Yang, Y. L., He, S. H., Miao, D. S., He, L., and Bi, Z. G. (2010) *Oncogene*, in press
13. Shaw, R. J., Kosmatka, M., Bardeesy, N., Hurley, R. L., Witters, L. A., DePinho, R. A., and Cantley, L. C. (2004) *Proc. Natl. Acad. Sci. U.S.A.* 101, 3329–3335
14. Xie, Z., Dong, Y., Zhang, M., Cui, M. Z., Cohen, R. A., Riek, U., Neumann, ...
D., Schlattner, U., and Zou, M. H. (2006) J. Biol. Chem. 281, 6366–6375
15. Winder, W. W., and Hardie, D. G. (1996) Am. J. Physiol. Endocrinol. Metab. 270, E299–E304
16. Kim, D. S., Woo, E. R., Chae, S. W., Ha, K. C., Lee, G. H., Hong, S. T., Kwon, D. Y., Kim, M. S., Jung, Y. K., Kim, H. M., Kim, H. K., Kim, H. R., and Chae, H. J. (2007) Life Sci. 80, 314–323
17. Zhang, J. F., Liu, J. J., Lu, M. Q., Cai, C. J., Yang, Y., Li, H., Xu, C., and Chen, G. H. (2007) Transpl. Immunol. 17, 162–168
18. Kim, W. H., Lee, J. W., Suh, Y. H., Lee, H. J., Lee, S. H., Oh, Y. K., Gao, B., and Jung, M. H. (2007) Cell. Signal. 19, 791–805
19. Preuss, I., Thust, R., and Kaina, B. (1996) Int. J. Cancer 65, 506–512
20. Kaina, B., Fritz, G., Mitra, S., and Coquerelle, T. (1991) Carcinogenesis 12, 1857–1867
21. Hermissen, M., Klumpp, A., Wick, W., Wischhusen, J., Nagel, G., Roos, W., Kaina, B., and Weller, M. (2006) J. Neurochem. 96, 766–776
22. Tentori, L., Lacal, P. M., Benincasa, E., Franco, D., Faraoni, I., Bonmassar, E., and Graziani, G. (1998) J. Pharmacol. Exp. Ther. 285, 884–893
23. D’Atri, S., Tentori, L., Lacal, P. M., Graziani, G., Pagani, E., Benincasa, E., Zambruno, G., Bonmassar, E., and Jiricny, J. (1998) Mol. Pharmacol. 54, 334–341
24. Naumann, S. C., Roos, W. P., Jöst, E., Belohlavek, C., Lennertz, V., Schmidt, C. W., Christmann, M., and Kaina, B. (2009) Br. J. Cancer 100, 322–333
25. Armstrong, J. L., Veal, G. J., Redfern, C. P., and Lovat, P. E. (2007) Apoptosis 12, 613–622
26. Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., and Shaw, R. J. (2008) Mol. Cell 30, 214–226
27. Gleason, C. E., Lu, D., Witters, L. A., Newgard, C. B., and Birnbaum, M. J. (2007) J. Biol. Chem. 282, 10341–10351
28. Romano, M. F., Avellino, R., Petrella, A., Bisogni, R., Romano, S., and Venuta, S. (2004) Eur. J. Cancer 40, 2829–2836
29. Meikrantz, W., Bergom, M. A., Memisoglu, A., and Samson, L. (1998) Carcinogenesis 19, 369–372
30. Kaina, B., Ziouta, A., Ochs, K., and Coquerelle, T. (1997) Mutat. Res. 381, 227–241
31. Hirose, M., and Kuroda, Y. (1998) Cancer Lett. 129, 165–171
32. Hirose, Y., Berger, M. S., and Pieper, R. O. (2001) Cancer Res. 61, 5843–5849
33. Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T., and Tanaka, N. (2000) Science 288, 1053–1058
34. Bocangel, D. B., Finkelstein, S., Schold, S. C., Bhakat, K. K., Mitra, S., and Kokkinakis, D. M. (2002) Clin. Cancer Res. 8, 2725–2734
35. Imamura, K., Ogura, T., Kishimoto, A., Kaminishi, M., and Esumi, H. (2001) Biochem. Biophys. Res. Commun. 287, 562–567
36. Boile, A. M., and Dong, Z. (2004) Nat. Rev. Cancer 4, 793–805
37. Jimenez, A. I., Fernandez, P., Dominguez, O., Dopazo, A., and Sanchez-Cespedes, M. (2003) Cancer Res. 63, 1382–1388
38. Inoki, K., Zhu, T., and Guan, K. L. (2003) Cell 115, 577–590
39. Cheng, S. W., Fryer, L. G., Carling, D., and Shepherd, P. R. (2004) J. Biol. Chem. 279, 15719–15722
40. Cantley, L. C., and Neel, B. G. (1999) Proc. Natl. Acad. Sci. U.S.A. 96, 4240–4245
41. Zhou, B. P., and Hung, M. C. (2003) Semin. Oncol. 30, 38–48